Physician profile
Ann Segeren
NPI 1447446794
$171,524.86
in general payments reported to CMS, 2019-2025
25 companies · $43K in 2025
The $43K reported for 2025 was more than what 98% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,291 · 2020: $18K · 2021: $19K · 2022: $31K · 2023: $34K · 2024: $26K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $82K · Travel and Lodging: $9,270 · Consulting Fee: $7,645 · Food and Beverage: $3,728 · Education: $89.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $81,664.33 |
| Travel and Lodging | $9,270.27 |
| Consulting Fee | $7,645.35 |
| Food and Beverage | $3,727.75 |
| Education | $89.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $100,113.21 | 2022-2025 | |
| Eisai INC. | $16,814.80 | 2019-2022 | |
| Aquestive Therapeutics, INC. | $16,676.43 | 2020-2022 | |
| Neurelis, INC. | $13,650.77 | 2020-2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $7,645.15 | 2020-2021 | |
| Greenwich Biosciences, INC. | $5,198.41 | 2019-2021 | |
| Neuropace, INC. | $3,077.49 | 2019-2025 | |
| Immedica Pharma US, INC. | $2,937.70 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $2,299.35 | 2023 | |
| H. Lundbeck A S | $1,079.19 | 2024 | |
| Ucb, INC. | $634.72 | 2019-2021 | |
| Livanova USA, INC. | $489.26 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Medtronic USA, INC. | $178.27 | 2019 | |
| Biocodex, INC. | $111.91 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $109.48 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $85.88 | 2021-2024 | Xcopri |
| Octapharma USA, INC. | $82.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $75.13 | 2019-2021 | |
| Zogenix INC. | $73.84 | 2021 | |
| Biomarin Pharmaceutical INC. | $69.33 | 2019 | |
| Corium, LLC | $50.08 | 2021 | |
| Ns Pharma, INC. | $35.31 | 2021 | |
| Biogen, INC. | $21.97 | 2021 | |
| Ironshore Pharmaceuticals INC. | $14.26 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Segeren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.